Interstitial Lung Disease Market Poised for Significant Growth from 2023 to 2032, Reports DelveInsight | J2H Biotech, Crystec Pharma, Apie Therapeutics, BLR Bio, ImmunoMet Therapeutics, AdAlta

The Key Interstitial Lung Disease Companies in the market include - J2H Biotech, Crystec Pharma, Apie Therapeutics, BLR Bio, ImmunoMet Therapeutics, AdAlta Limited, Genentech, Bristol-Myers Squibb, Sunshine Lake Pharma, aTyr Pharma, FibroGen, Boehringer Ingelheim, and others.

DelveInsight's "Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Interstitial Lung Disease, historical and forecasted epidemiology as well as the Interstitial Lung Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Interstitial Lung Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Interstitial Lung Disease Market Forecast [https://www.delveinsight.com/sample-request/interstitial-lung-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Interstitial Lung Disease Market Report:

*
The Interstitial Lung Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

*
In February 2025, Boehringer Ingelheim's lung disease treatment, nerandomilast, has achieved success in a Phase III trial, positioning the company to pursue approval for its use in a second condition. Topline results from the Phase III FIBRONEER-ILD study (NCT05321082) indicate that nerandomilast enhanced lung function in patients with progressive fibrosing interstitial lung diseases (PF-ILDs), excluding idiopathic pulmonary fibrosis (IPF). Previously, the company conducted a separate IPF trial, which contributed to its new drug application (NDA) submission last year.

*
Key Interstitial Lung Disease Companies: J2H Biotech, Crystec Pharma, Apie Therapeutics, BLR Bio, ImmunoMet Therapeutics, AdAlta Limited, Genentech, Bristol-Myers Squibb, Sunshine Lake Pharma, aTyr Pharma, FibroGen, Boehringer Ingelheim, and others

*
Key Interstitial Lung Disease Therapies: J2H P1905, CR405, APT-101, BLR-200, M-156, AD-214, Vixarelimab, Abatacept, HEC585, Efzofitimod, Pamrevlumab, BI-1015550, and others

*
The Interstitial Lung Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Interstitial Lung Disease pipeline products will significantly revolutionize the Interstitial Lung Disease market dynamics.

Interstitial Lung Disease Overview

Interstitial lung disease (ILD) is a broad term that refers to a group of lung disorders characterized by inflammation and scarring (fibrosis) of the interstitium, which is the tissue that surrounds and supports the air sacs (alveoli) in the lungs. This inflammation and scarring can impair the ability of the lungs to function properly, leading to symptoms such as cough, shortness of breath, and decreased exercise tolerance.

Get a Free sample for the Interstitial Lung Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/interstitial-lung-disease-market [https://www.delveinsight.com/report-store/interstitial-lung-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Interstitial Lung Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Interstitial Lung Disease Epidemiology Segmentation:

The Interstitial Lung Disease market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Interstitial Lung Disease

*
Prevalent Cases of Interstitial Lung Disease by severity

*
Gender-specific Prevalence of Interstitial Lung Disease

*
Diagnosed Cases of Episodic and Chronic Interstitial Lung Disease

Download the report to understand which factors are driving Interstitial Lung Disease epidemiology trends @ Interstitial Lung Disease Epidemiology Forecast [https://www.delveinsight.com/sample-request/interstitial-lung-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Interstitial Lung Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Interstitial Lung Disease market or expected to get launched during the study period. The analysis covers Interstitial Lung Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Interstitial Lung Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Interstitial Lung Disease Therapies and Key Companies

*
J2H P1905: J2H Biotech

*
CR405: Crystec Pharma

*
APT-101: Apie Therapeutics

*
BLR-200: BLR Bio

*
M-156: ImmunoMet Therapeutics

*
AD-214: AdAlta Limited

*
Vixarelimab: Genentech

*
Abatacept: Bristol-Myers Squibb

*
HEC585: Sunshine Lake Pharma

*
Efzofitimod: aTyr Pharma

*
Pamrevlumab: FibroGen

*
BI-1015550: Boehringer Ingelheim

Discover more about therapies set to grab major Interstitial Lung Disease market share @ Interstitial Lung Disease Treatment Landscape [https://www.delveinsight.com/sample-request/interstitial-lung-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Interstitial Lung Disease Market Drivers

*
Increase in prevalence of Interstitial Lung Disease (ILD), increase in geriatric population are some of the important factors that are fueling the Interstitial Lung Disease Market.

Interstitial Lung Disease Market Barriers

*
However, frequent misdiagnosis of the disease, costly and invasive diagnostic procedures and other factors are creating obstacles in the Interstitial Lung Disease Market growth.

Scope of the Interstitial Lung Disease Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Interstitial Lung Disease Companies: J2H Biotech, Crystec Pharma, Apie Therapeutics, BLR Bio, ImmunoMet Therapeutics, AdAlta Limited, Genentech, Bristol-Myers Squibb, Sunshine Lake Pharma, aTyr Pharma, FibroGen, Boehringer Ingelheim, and others

*
Key Interstitial Lung Disease Therapies: J2H P1905, CR405, APT-101, BLR-200, M-156, AD-214, Vixarelimab, Abatacept, HEC585, Efzofitimod, Pamrevlumab, BI-1015550, and others

*
Interstitial Lung Disease Therapeutic Assessment: Interstitial Lung Disease current marketed and Interstitial Lung Disease emerging therapies

*
Interstitial Lung Disease Market Dynamics: Interstitial Lung Disease market drivers and Interstitial Lung Disease market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Interstitial Lung Disease Unmet Needs, KOL's views, Analyst's views, Interstitial Lung Disease Market Access and Reimbursement

To know more about Interstitial Lung Disease companies working in the treatment market, visit @ Interstitial Lung Disease Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/interstitial-lung-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Interstitial Lung Disease Market Report Introduction

2. Executive Summary for Interstitial Lung Disease

3. SWOT analysis of Interstitial Lung Disease

4. Interstitial Lung Disease Patient Share (%) Overview at a Glance

5. Interstitial Lung Disease Market Overview at a Glance

6. Interstitial Lung Disease Disease Background and Overview

7. Interstitial Lung Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Interstitial Lung Disease

9. Interstitial Lung Disease Current Treatment and Medical Practices

10. Interstitial Lung Disease Unmet Needs

11. Interstitial Lung Disease Emerging Therapies

12. Interstitial Lung Disease Market Outlook

13. Country-Wise Interstitial Lung Disease Market Analysis (2019-2032)

14. Interstitial Lung Disease Market Access and Reimbursement of Therapies

15. Interstitial Lung Disease Market Drivers

16. Interstitial Lung Disease Market Barriers

17. Interstitial Lung Disease Appendix

18. Interstitial Lung Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=interstitial-lung-disease-market-poised-for-significant-growth-from-2023-to-2032-reports-delveinsight-j2h-biotech-crystec-pharma-apie-therapeutics-blr-bio-immunomet-therapeutics-adalta]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.